Modified FOLFIRINOX

Phase 2

ABBOTT LABORATORIES (ABT)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

ABTPhase 2$180.5B

Modified FOLFIRINOX Phase 2 Est. Readout

Modified FOLFIRINOX• Locally Advanced Pancreatic Adenocarcinoma25

Dec 2026~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Locally Advanced Pancreatic Adenocarcinoma

View Full Landscape

Drug Information

Target Indication

Locally Advanced Pancreatic Adenocarcinoma

Clinical Trial

NCT06850623

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ABT

ABBOTT LABORATORIES

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Kaletra (lopinavir/ritonavir)Phase 3

HIV Infections

clarithromycin immediate-release tabletsPhase 3

Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB).

ZemplarPhase 3

Chronic Kidney Disease

Adalimumab every other weekPhase 3

Plaque Psoriasis

Adalimumab Every WeekPhase 3

Plaque Psoriasis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts